221 related articles for article (PubMed ID: 11979888)
1. [Cause and prevention of nocturnal gastric acid breakthrough].
Adachi K; Kinoshita Y
Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
[No Abstract] [Full Text] [Related]
2. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
3. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
[TBL] [Abstract][Full Text] [Related]
4. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Shirai N; Furuta T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
[No Abstract] [Full Text] [Related]
5. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
6. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
7. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
8. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
9. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
12. [Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Okudaira K; Miura S; Furuta T; Sugimoto M; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():391-6. PubMed ID: 16363566
[No Abstract] [Full Text] [Related]
13. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Homma M; Itagaki F; Yuzawa K; Fukao K; Kohda Y
Transplantation; 2002 Jan; 73(2):303-4. PubMed ID: 11821750
[No Abstract] [Full Text] [Related]
14. [Investigation about 3rd line eradication of H. pylori].
Nakagawa S; Kato M; Shimizu Y; Nakagawa M; Asaka M
Nihon Rinsho; 2005 Nov; 63 Suppl 11():466-9. PubMed ID: 16363580
[No Abstract] [Full Text] [Related]
15. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
16. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
17. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
18. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
19. Determinants of non-response in Helicobacter pylori eradication trials.
Klotz U; Treiber G; Schwab M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1471. PubMed ID: 16105147
[No Abstract] [Full Text] [Related]
20. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]